QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=D843C6311E59698C2DBE7AF30DE6C714;jsessionid=6C5D62AE93482B6A6478C1D31B2CD075;jsessionid=86B0E0C732792DFC74B9E6F75080E21A;jsessionid=A048716453AE9E862B253EFC0AB2139F;jsessionid=FB676FF3530893FF1F71B48A8C3A521D;jsessionid=2F84F2DB34749622E9B24E825A1F34F0 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=D843C6311E59698C2DBE7AF30DE6C714;jsessionid=6C5D62AE93482B6A6478C1D31B2CD075;jsessionid=86B0E0C732792DFC74B9E6F75080E21A;jsessionid=A048716453AE9E862B253EFC0AB2139F;jsessionid=FB676FF3530893FF1F71B48A8C3A521D;jsessionid=2F84F2DB34749622E9B24E825A1F34F0